Sutro Biopharma (STRO) Interest Expenses (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Interest Expenses data on file, last reported at $19.7 million in Q3 2025.

• For the quarter ending Q3 2025, Interest Expenses rose 137.75% year-over-year to $19.7 million; the trailing twelve-month figure through Dec 2025 stood at $6.9 million (up 36.5% YoY), and the FY2025 full-year result was $272.2 million, up 19.47% from the prior year.
• Interest Expenses declined to $19.7 million in Q3 2025, from $22.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $40.6 million in Q2 2023 to a low of -$2.0 million in Q4 2021.
• A 5-year average of $9.6 million and a median of $2.3 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses tumbled 272.16% in 2021 and soared 6660.83% in 2023, its largest moves.
• Tracing STRO's Interest Expenses over 5 years: stood at -$2.0 million in 2021, then jumped by 113.2% to $258000.0 in 2022, then tumbled by 39.92% to $155000.0 in 2023, then jumped by 1383.87% to $2.3 million in 2024, then surged by 756.83% to $19.7 million in 2025.
• Business Quant data shows STRO's Interest Expenses at $19.7 million in Q3 2025, $22.1 million in Q2 2025, and $2.3 million in Q1 2025.